Tags |
|
|
Links |
|
|
Advice You - Marketing Management and the EU
Many of the marketing texts argue that marketing is a logical process with a natural structure which can be viewed primarily as a method of: understanding the marketing env
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ironment; using the marketing mix; developing a marketing plan based upon the use of the mix; implementing a plan through a strategy; and finally, using a control method to
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
ensure the strategy is adhered to. This marketing process is reviewed and evaluated regularly and modifications made to the use of the mix to take account of market changes
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
impacting upon competitiveness. This view of marketing seems to suggest that much of the marketing theory relate to multinational enterprises, which are internationally bas
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
ed and have global ambitions. The EU market constitutes a differentiated marketplace in terms of culture, competition, and organization strategies used to penetrate the tar
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
et market. Although these differences have their implications interfere with a country's business planning, EU is considered as an opportunity for companies worldwide to ex
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
and through internationalization strategies and compete with major players in terms of sales, profits, market shares and organizational momentum.
Another core issue in mar
Another core issue in mar
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
keting is the growth and importance of theories in networking and interaction. This view looks at the way in which companies and organizations interact and consequently net
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ork with each other to gain commercial advantage in world markets. The network can be using similar subcontractors or components, sharing research and development costs or
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
perating within the same governmental framework. Clearly, being within the EU, a trading block with no internal barriers creates its own networks. Collaborations in aerospa
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
e, vehicle manufactures and engineering have all sponsored the development of a European outlook based on its own internal market network. This network and interaction appr
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
oach to marketing shows the substance of being able to influence decisions by knowledge of how the EU network works or interacts.
The EU is a rich, diverse market, with a
The EU is a rich, diverse market, with a
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ibrant and varied cultural heritage; this means that although there has been a harmonization process within the 15 states as a result of the formation of EU, there are stil
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
differences. Rather than business being simpler as a result of the union, it should be recognized that because of regulation and need to restructure in a global market it
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
can be highly complex. It should be remembered that the Europeans have a high-income average and like to have their cultural differences recognized. Those firms that will o
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
have recognized this have a good chance of developing a successful marketing strategy to meet their needs.
Furthermore the marketing operations of EU companies need to be
Furthermore the marketing operations of EU companies need to be
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
adapted in order to respond to the multiple of changes which have taken place in Europe. However, it is not possible to identify clearly how companies should modify their m
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
arketing operations. Some companies face radical change to overall strategy as well as to marketing operations. Other companies are more likely to consider minor alteration
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
to their existing strategies and marketing initiatives. The only "golden rule" as is so often the case is that there are no "golden rules." EU companies need to assess the
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
r marketing response to the changes in the European environment, on the basis of careful studying the effects of these changes on their current and likely future activities
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/27214/adviceyou-Marketing-Management-and-the-EU.html">Marketing Management and the EU</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/27214/adviceyou-Marketing-Management-and-the-EU.html]Marketing Management and the EU[/url]
Related Articles:
Bright Future For Indian Textile Industry
IS CRM THE BEST TOOL EVER CAME INTO EXISTENCE -- NOT REALLY
Bookmark it:
|